Efficacy and safety of implantable cardioverter-defibrillator implantation in the elderly-The I-70 Study: A randomized clinical trial.

Elderly Electrophysiology Heart failure Implantable cardioverter-defibrillator Primary prevention

Journal

Heart rhythm O2
ISSN: 2666-5018
Titre abrégé: Heart Rhythm O2
Pays: United States
ID NLM: 101768511

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 10 7 2024
Statut: epublish

Résumé

There is conflicting evidence on the efficacy of primary prevention implantable cardioverter-defibrillator (ICD) implantation in the elderly. The purpose of this study was to determine the efficacy and safety of ICD implantation in patients 70 years and older. Patients (n = 167) aged 70 years or older and eligible for ICD implantation were randomly assigned (1:1) to receive either optimal medical therapy (OMT) (n = 85) or OMT plus ICD (n = 82). Of the 167 participants (mean age 76.4 years; 165 men), 144 completed the study protocol according to their assigned treatment. Average participant follow-up was 31.5 months. Mortality was similar between the 2 groups: 27 deaths in OMT vs 26 death in ICD (unadjusted hazard ratio 0.92; 95% confidence interval 0.53-1.57), but there was a trend favoring the ICD over the first 36 months of follow-up. Rates of sudden death (7 vs 5; The study did not recruit to target sample size, and accumulated data did not show benefit of ICD therapy in patients 70 years or older. Future studies similar in design might be feasible but will need to contend with patient treatment preference given the large number of patients who do not want an ICD implanted. Further research is needed to determine whether the ICD is effective in prolonging life among elderly device candidates.

Sections du résumé

Background UNASSIGNED
There is conflicting evidence on the efficacy of primary prevention implantable cardioverter-defibrillator (ICD) implantation in the elderly.
Objective UNASSIGNED
The purpose of this study was to determine the efficacy and safety of ICD implantation in patients 70 years and older.
Methods UNASSIGNED
Patients (n = 167) aged 70 years or older and eligible for ICD implantation were randomly assigned (1:1) to receive either optimal medical therapy (OMT) (n = 85) or OMT plus ICD (n = 82).
Results UNASSIGNED
Of the 167 participants (mean age 76.4 years; 165 men), 144 completed the study protocol according to their assigned treatment. Average participant follow-up was 31.5 months. Mortality was similar between the 2 groups: 27 deaths in OMT vs 26 death in ICD (unadjusted hazard ratio 0.92; 95% confidence interval 0.53-1.57), but there was a trend favoring the ICD over the first 36 months of follow-up. Rates of sudden death (7 vs 5;
Conclusion UNASSIGNED
The study did not recruit to target sample size, and accumulated data did not show benefit of ICD therapy in patients 70 years or older. Future studies similar in design might be feasible but will need to contend with patient treatment preference given the large number of patients who do not want an ICD implanted. Further research is needed to determine whether the ICD is effective in prolonging life among elderly device candidates.

Identifiants

pubmed: 38984364
doi: 10.1016/j.hroo.2024.04.010
pii: S2666-5018(24)00105-3
pmc: PMC11228113
doi:

Types de publication

Journal Article

Langues

eng

Pagination

365-373

Auteurs

Steven N Singh (SN)

Veterans Affairs Medical Center, Washington, DC.
Georgetown University, Washington, DC.

Michael Wininger (M)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.
Yale School of Public Health, New Haven, Connecticut.

Merritt Raitt (M)

VA Portland Healthcare System, Portland, Oregon.
Oregon Health and Sciences University, Portland, Oregon.

Selcuk Adabag (S)

Minneapolis VA Medical Center, Minneapolis, Minnesota.
University of Minnesota, Minneapolis, Minnesota.

Hans Moore (H)

Veterans Affairs Medical Center, Washington, DC.
Georgetown University, Washington, DC.
George Washington University School of Medicine and Health Sciences, Washington, DC.

Jeffrey N Rottman (JN)

Baltimore VA Medical Center, Baltimore, Maryland.
University of Maryland, Baltimore, Maryland.

Alexandra Scrymgeour (A)

Cooperative Studies Program Research Pharmacy Coordinating Center, Albuquerque, New Mexico.

Jane Zhang (J)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.

Kevin Zheng (K)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.

Peter Guarino (P)

Fred Hutchinson Cancer Center, Seattle, Washington.

Tassos C Kyriakides (TC)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.
Yale School of Public Health, New Haven, Connecticut.

Gary Johnson (G)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.

Alicia Williams (A)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.

Alex Beed (A)

Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, Connecticut.

Karen MacMurdy (K)

VA Portland Healthcare System, Portland, Oregon.
Oregon Health and Sciences University, Portland, Oregon.

Pablo Saavedra (P)

Nashville VA Medical Center, Nashville, Tennessee.
Vanderbilt University Medical Center, Nashville, Tennessee.

Classifications MeSH